The BRAF-mutated NSCLC market is poised for growth due to an increasing incidence rate across 7MM. Currently, only one approved therapy, the Tafinlar and Mekinist combo, targets this mutation.
SHANGHAI, April 10 (Reuters) - Amgen's lung cancer drug tarlatamab has won approval from China's National Medical Products Administration, its development and commercialisation partner BeOne Medicines ...
A new study co-led by the Institute for Systems Biology (ISB) shows that some lung cancers can change identity as they evolve ...
If approved, ifinatamab deruxtecan would be a first-in-class B7-H3 directed DXd antibody drug conjugate for these patients ...
Morning Overview on MSN
New ORACLE gene test flags lung cancer spread risk before surgery
A patient walks into a thoracic surgery consultation with a small lung tumor, stage I on every scan, and every conventional ...
Squamous cell carcinoma treatment varies by stage, involving surgery, radiation, and systemic therapies based on cancer progression and patient health. Stage 1 focuses on tumor removal, Stage 2 ...
HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...
New research suggests heavy marijuana smoking may raise the risk of lung cancer risk, as well as head and neck cancer.
You and your family are our top priority. At Fred Hutch Cancer Center, we offer comprehensive and compassionate care — personalized to you. You'll have access to the latest treatment options, clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results